Shots:

• The 1st patient has been enrolled in P-IIb (TREK-AD) dose-ranging clinical study to evaluate efficacy & safety of eblasakimab (300/400mg, q2w, 400/600mg, q4w) in 300 patients with AD across 100 sites in North America, EU & Asia Pacific.  The results from the 16wk. treatment period is expected in H1’23
• The primary efficacy EPs is the percentage change in EASI score from baseline to 16wk. The 2EPs include the proportion of patients who achieve an IGA score of 0 (clear) or 1 (almost clear), ≥75% reduction in EASI-75 & achieve EASI-50 & 90 & changes in peak pruritus
• Eblasakimab is a mAb targeting IL-13 receptor & has the potential to provide a differentiated treatment option for patients

Ref: Globe Newswire | Image: Stock Light